Valuation: Haleon plc

Capitalization 32.26B 43.2B 37.21B 34.68B 60.01B 3,903B 64.38B 398B 157B 1,866B 162B 159B 6,845B P/E ratio 2025 *
20.8x
P/E ratio 2026 * 19.2x
Enterprise value 39.81B 53.3B 45.91B 42.79B 74.05B 4,816B 79.44B 492B 193B 2,302B 200B 196B 8,446B EV / Sales 2025 *
3.59x
EV / Sales 2026 * 3.39x
Free-Float
89.25%
Yield 2025 *
1.94%
Yield 2026 * 2.18%
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.07%
1 week-3.03%
Current month-3.36%
1 month+1.03%
3 months+5.44%
6 months-1.36%
Current year-3.36%
More quotes
1 week 358.9
Extreme 358.9
374.2
1 month 358.9
Extreme 358.9
380.8
Current year 358.9
Extreme 358.9
380.8
1 year 274.4
Extreme 274.4
419.5
3 years 274.4
Extreme 274.4
419.5
5 years 241.17
Extreme 241.1735
419.5
10 years 241.17
Extreme 241.1735
419.5
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 21/07/2021
Director of Finance/CFO 56 31/10/2024
Chief Tech/Sci/R&D Officer 63 31/07/2025
Director TitleAgeSince
Director/Board Member 59 22/05/2022
Chairman 71 31/12/2025
Director/Board Member 58 17/07/2022
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.07%-3.03%-1.33%+11.45% 43.86B
-3.76%-6.78%+38.67%+185.65% 961B
+0.47%+5.82%+51.69%+26.60% 527B
-2.32%-7.14%+23.47%+41.11% 392B
+0.46%+2.22%+31.25%+18.51% 368B
-2.23%-1.39%+31.95%+20.33% 299B
-1.36%+0.77%+27.04%+35.48% 279B
-0.04%+2.18%+11.36%-1.14% 276B
-3.45%-0.33%-38.34%-22.02% 262B
+0.32%-3.40%+23.56%+21.46% 177B
Average -1.30%+0.18%+19.93%+33.74% 358.45B
Weighted average by Cap. -1.69%+0.02%+27.72%+64.04%
See all sector performances

Financials

2025 *2026 *
Net sales 11.08B 14.84B 12.78B 11.91B 20.61B 1,340B 22.11B 137B 53.85B 641B 55.63B 54.5B 2,351B 11.57B 15.49B 13.35B 12.44B 21.53B 1,400B 23.09B 143B 56.23B 669B 58.1B 56.91B 2,455B
Net income 1.58B 2.12B 1.82B 1.7B 2.94B 191B 3.15B 19.52B 7.68B 91.41B 7.94B 7.77B 335B 1.69B 2.26B 1.94B 1.81B 3.14B 204B 3.36B 20.82B 8.19B 97.51B 8.47B 8.29B 358B
Net Debt 7.55B 10.1B 8.7B 8.11B 14.04B 913B 15.06B 93.2B 36.67B 436B 37.89B 37.12B 1,601B 6.94B 9.29B 8B 7.46B 12.91B 839B 13.85B 85.68B 33.72B 401B 34.83B 34.12B 1,472B
More financial data * Estimated data
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (29.5%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (22.8%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (17.7%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - vitamins, minerals and food supplements (15.1%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. - respiratory medicines (14.9%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.2%), North America (36%), and Asia/Pacific (22.8%).
Employees
24,561
More about the company
Date Price Change Volume
15/01/26 362.20 p -1.07% 11,809,150
14/01/26 366.10 p +1.02% 21,599,440
13/01/26 362.40 p +0.06% 12,660,110
12/01/26 362.20 p -1.44% 14,599,970
09/01/26 367.50 p -1.18% 13,550,360

Delayed Quote London S.E., January 15, 2026 at 04:35 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
3.622GBP
Average target price
4.169GBP
Spread / Average Target
+15.11%
Consensus

Quarterly revenue - Rate of surprise